Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc CLVS and TESARO Inc TSRO ahead of the Lynparza label decision. Read moreCLVS will break out the falling wedge soon. The forming of an upside trend is possible. $CLVS, Clovis Oncology, Inc. / H1 TSRO have some upside potential. Stochastics are in the oversold territory, so the shares even have chance to break out the falling channel. $TSRO, TESARO, Inc. / H1